BridGene Biosciences, Inc., a leader in the discovery and development of small molecule drugs for traditionally "hard-to-drug" targets, today announced the recent completion of a $28 million Series B+ ...
FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System Company Completes the Recruitment of its Commercial Leadership Team as it Remains On Track to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback